James T. Gaensbauer, M.D., M.S.

Closed for Enrollment

• A Phase 1, Open-Label, Non-Comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants with Nosocomial Pneumonia Rochester, Minn.

  The purpose of this study is helping researchers evaluate the pharmacokinetics (how the body handles a drug), safety, and tolerability of an investigational medication in children from birth (at least seven days postnatal) to less than 18 years of age with a diagnosis of confirmed or suspected nosocomial pneumonia (NP), including hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).